TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03562429
Drug: TGF
Normalized name: Anti-TGF-beta 2G7
DrugBank: 2G7 (DB18589)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TGF is a powder formulation of Hu-Qian Wan (HQW). HQW is composited of 10 herbs, Chinemys reevesii (Gray), Phellodendron chinense Schneid., Achyranthes bidentata Blume, Anemarrhena asphodeloides Bunge, Rehmannia glutinosa Libosch., Paeonia lactiflora Pall., Cynomorium songaricum Rupr., Angelica sinensis (Oliv.) Diels, Citrus reticulata Blanco and Zingiber officinale Rosc..
Study: NCT02342145
Drug: Basiliximab,
DrugBank: Basiliximab (DB00074)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Basiliximab was used 10mg each time on 0d(after transplantation) and +4 d .
Study: NCT01233609
Drug: Valproic Acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One to four 250mg softgels by mouth daily (dose determined by body weight)
Study: NCT02342145
Drug: cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specifically cyclosporine A was used by intravenous drip infusion on 2mg/kg dosage from -1d and change to 5mg/kg twice oral when gastrointestinal function recovers. The blood concentrations of cyclosporine A was maintained 150-250ng/ml.
Study: NCT03772951
Drug: Clozapine
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the course of disease is more than 2 years, the condition is stable for more than one month
Study: NCT02342145
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil was used 0.25g qd from 0d to 3 months for prevention of graft-versus-host-disease.
Study: NCT02400814
Drug: Anti-PD-L1 Monoclonal Antibody MPDL3280A
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT02394652
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin is an antidiabetic agent given orally.
Study: NCT02394652
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin is an antineoplastic agent given intravenously.
Study: NCT02394652
Drug: FAZA
Normalized name: Fazaclo
DrugBank: Fazadinium bromide (DB13745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAZA is an investigational imaging agent for positron emission tomography scans indicated for hypoxia.
Study: NCT01225913
Drug: fluticasone/salmeterol in all asthmatics
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: budesonide 80ug/formoterol 4.5ug, 2 inhalations bid X 20-60 days or fluticasone 100ug/salmeterol 50ug, 1 inhalation bid X 20-60 days
Study: NCT01046422
Drug: BMS-770767
Normalized name: BMS-770767
DrugBank: BMS-770767 (DB18902)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, Oral, 15mg, Active, Daily, 28 days
Study: NCT01225913
Drug: budesonide/formoterol or fluticasone/salmeterol in all asthmatics
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: budesonide 160ug/formoterol 4.5ug, 2 inhalations bid or fluticasone 250ug/salmeterol 50ug, 1 inhalations bid
Study: NCT00003344
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01046422
Drug: BMS-770767
Normalized name: BMS-770767
DrugBank: BMS-770767 (DB18902)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, Oral, 50mg, Active, Daily, 28 days
Study: NCT01046422
Drug: BMS-770767
Normalized name: BMS-770767
DrugBank: BMS-770767 (DB18902)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, Oral, 150mg, Active, Daily, 28 days
Study: NCT01046422
Drug: BMS-770767
Normalized name: BMS-770767
DrugBank: BMS-770767 (DB18902)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, Oral, 50mg BID, Active, Daily, 28 days
Study: NCT01046422
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet, Oral, ≥ 1500mg, Active, Daily, 28 days
Study: NCT04197479
Drug: Resmetirom
Normalized name: Resmetirom
DrugBank: Resmetirom (DB12914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT00884416
Drug: Sorafenib dose escalation
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib dose escalation scheme: 3 first patients: 200 mg/d, if dose limiting toxicities (DLT) not reached: 3 patients at 200 mg BID, if no DLT reached: 3 patients at 400 mg bid
Study: NCT01101061
Drug: Romosozumab
Normalized name: ROMOSOZUMAB
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered by subcutaneous injection
Study: NCT02621255
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthesia type of performed for patient which has femur fracture.
Study: NCT02033473
Drug: Apelin
Normalized name: Apelin
DrugBank: Apelin (DB18909)
Approvals — FDA: no, EMA: no, PMDA: no
Description: An apelin clamp in which an apelin infusion will be administered
Study: NCT01993849
Drug: N-Acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This is the medication N-acetylcysteine (NAC)
Study: NCT02621255
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthesia type of performed for patient which has femur fracture.
Study: NCT01363310
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage form: tablets Day 1-2: 50 mg Day 3-7: 150 mg Day 8-57: either 150 or 300 mg/day (flexible)
Study: NCT01363310
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage form: capsules Day 1-7: 10 mg Day 8-57: 10 or 20 mg/day (flexible)
Study: NCT01114308
Drug: Probuphine (buprenorphine implant)
Normalized name: Probuphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug.
Study: NCT01114308
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: sublingual buprenorphine/naloxone tablets
Study: NCT00002536
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002536
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00239447
Drug: Tiotropium
Normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01137747
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01426113
Drug: bimatoprost ophthalmic solution formulation A
Normalized name: bimatoprost Ophthalmic Solution
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 drop of bimatoprost ophthalmic solution formulation A in the affected eye(s) in the evening for 6 weeks, followed by 1 drop of bimatoprost ophthalmic solution formulation A in the affected eye(s) in the morning for 6 weeks.
Study: NCT01426113
Drug: timolol ophthalmic solution
Normalized name: timolol Ophthalmic Solution
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 drop timolol ophthalmic solution in the affected eye(s) in the morning and evening for 12 weeks.
Study: NCT00296387
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00641173
Drug: paroxetine
Normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: treatment with SSRI paroxetine
Study: NCT00216450
Drug: rabeprazole sodium
Normalized name: Rabeprazole Sodium
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00460148
Drug: Ropinirole
Normalized name: Ropinirole
DrugBank: Ropinirole (DB00268)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01426113
Drug: bimatoprost vehicle
Normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 drop of bimatoprost vehicle in the affected eye(s) in the morning for 6 weeks, followed by 1 drop of bimatoprost vehicle in the affected eye(s) in the evening for 6 weeks.
Study: NCT02472054
Drug: Alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02472054
Drug: Methyl Prednisolone (MP)
Normalized name: Prednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02472054
Drug: Cyclosporin A (CSA)
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00168493
Drug: antidepressants primarily selective serotonin reuptake inhibitors
Normalized name: serotonin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal clinical dosages used according to clinical response as determined by a psychiatrist
Study: NCT00479219
Drug: GSI-953
Normalized name: GSI-136
DrugBank: GSI-136 (DB12819)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00532246
Drug: raloxifene
Normalized name: Raloxifene
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03446638
Drug: FDA-approved drug or combination of drugs
Normalized name: afamelanotide
DrugBank: Afamelanotide (DB04931)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients assigned to this arm will receive an FDA-approved drug or combination of drugs. Dosing and treatment schedule will follow the package insert for the selected drug(s).
Study: NCT03446638
Drug: 7 + 3 induction
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive 100-200 mg/m2 per day intravenously of cytarabine for 7 days, plus either 45-60 mg/m2 per day intravenously of daunorubicin or 9-12 mg/m2 per day intravenously of idarubicin for 3 days.
Study: NCT03446638
Drug: Low-dose cytarabine
Normalized name: ethinyl estradiol
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive 20 mg/m2 per day subcutaneously of cytarabine for 10 days every 28 days.
Study: NCT04751136
Drug: cerebrolysin
Normalized name: cerebrolysin
DrugBank: Cerebrolysin (DB16599)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infants of the treatment group were given Cerebrolysin in a dose of 0.1 ml / kg body weight once weekly intramuscular injection for 12 month (total of 48 injections).Each selected infant, in both treatment and control group, was assessed as regard: Socioeconomic status, Nutritional status and feeding practice, assessed for neurocognitive development
Study: NCT02722811
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: etanercept of 50 mg/w, subcutaneous injection; treatment: 8 weeks
Study: NCT01398098
Drug: Sodium phosphate
Normalized name: Sodium Phosphate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 32 tablets
Study: NCT00001509
Drug: IFN-alpha with retinoic acid
Normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04138342
Drug: Quantum dots coated with veldoreotide
Normalized name: D3 Dots
DrugBank: Veldoreotide (DB12777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The active group will receive Quantum dots coated with veldoreotide in different topical dosage forms as an anti-cancer drug.
Study: NCT03713320
Drug: Cobomarsen
Normalized name: Cobomarsen
DrugBank: Cobomarsen (DB14931)
Approvals — FDA: no, EMA: no, PMDA: no
Description: At least weekly doses of cobomarsen (282 mg) throughout study treatment period
Study: NCT03713320
Drug: Vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily doses of vorinostat throughout study treatment period
Study: NCT00433875
Drug: AMG 714
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02271230
Drug: Vitamin D and fish oil
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 IU vitamin D and 1g/d fish oil
Study: NCT04026945
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release lidocaine injection
Study: NCT01099579
Drug: Atazanavir powder
Normalized name: atazanavir Oral Powder
DrugBank: Atazanavir (DB01072)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Powder, oral, dosed by weight. Participants who weighed 5 to \<10 kg received atazanavir (ATV), 150 mg, and ritonavir (RTV), 80 mg; those who weighed 10 to \<15 kg received ATV, 200 mg, and RTV, 80 mg; and those who weighed 15 to \<25 kg received ATV, 250 mg, and RTV, 80 mg, once per day for 48 weeks or until pediatric indication is locally approved and participant meets requirements to receive appropriate formulation.
Study: NCT01099579
Drug: Ritonavir oral solution
Normalized name: Ritonavir Oral Solution
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral solution, 80 mg/mL, once per day for 48 weeks or until pediatric indication is locally approved and participant meets requirements to receive appropriate formulation.
Study: NCT01099579
Drug: Atazanavir capsules
Normalized name: Atazanavir Capsules
DrugBank: Atazanavir (DB01072)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsules, oral, dosed by weight in Stage 2. Patients who reached the age of 6 years or a weight of ≥25 kg transitioned from the powder to the capsule formulation of atazanavir (ATV). Patients who weighed 15 to \<20 kg received ATV, 150 mg with RTV, 100 mg; those who weighed 20 to \<40 kg received ATV, 200 mg, and RTV, 100 mg; and those who weighed at least 40 kg received ATV, 300 mg with RTV, 100 mg. RTV capsules or tablets were ingested with food immediately before or after ATV intake.
Study: NCT01099579
Drug: Ritonavir capsules
Normalized name: Ritonavir Capsules
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral, capsules, 100 mg, administered in Stage 2 with atazanavir capsules, dosed by weight.
Study: NCT00503503
Drug: Enbrel (etanercept)
Normalized name: etanercept Cartridge [Enbrel]
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02489409
Drug: EndostarTM Injection
Normalized name: Endostar
DrugBank: Endostar (DB11727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 210 mg in 279 mL normal saline (NS), continuous pump, d1-d10 (2.5 mL/h)
Study: NCT02489409
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1.0 m/m2, iv 0.5h, d1, 8
Study: NCT02489409
Drug: Navelbine
Normalized name: Navelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg/d, iv, d1, 8
Study: NCT02489409
Drug: Platinum
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/m2, iv 3h, d1-3
Study: NCT00020722
Drug: Ifosfamide, carboplatin, and etoposide (ICE) regimen
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ifosfamide 2,500 mg/m2 given IV daily on day -8, -7, -6, -5, -4, and -3 prior to PBSCT. Ifosfamide 2,500 mg/m2 infused IV over 1 hour (hour 0-1) on days -8 to -3 for a total dose of 15,000 mg/m2.~Mesna will be administered per BMT Standard of Care Guideline at a dose of 25% of the total Ifosfamide dose 30 minutes prior to and then 3, 6, and 9 hours after ifosfamide daily on days -8, -7, -6, -5, -4, and -3 prior to PBSCT for a total dose of 2500 mg/m2.~Carboplatin at a dose of 250 mg/m2 will be given daily on days -8, -7, -6, -5, -4, and -3 prior to PBSCT for a total dose of 1500 mg/m2.~VP-16 (etoposide) at a dose of 200 mg/m2 will be given IV on days -8, -7, -6, -5, -4 and -3. The total dose of VP-16 given prior to PBSCT will be 2,400 mg/m2. VP-16 will be given 200 mg/m2
Study: NCT03363659
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide is taken once daily
Study: NCT04543812
Drug: Ferric citrate
Normalized name: Ferric Citrate
DrugBank: Ferric sulfate (DB11171)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric citrate will be provided as a 1g tablet. All intervention doses will be based on hemoglobin levels.
Study: NCT01130168
Drug: Comparator: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 10 mg, taken orally as two 5 mg capsules, single daily dose for 4 weeks
Study: NCT02087215
Drug: boron gel
DrugBank: Boron (DB11203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: application of a formulation gel: addition of borate as sodium penta boric acid pentahydrate 3% (w/v) and two different copolymer as pluronic block namely F68 2% (w/v) and f127 2% (w/v) to diabetic foot ulcers.
Study: NCT01688960
Drug: nesvacumab (REGN910/ SAR307746)
Normalized name: Nesvacumab
DrugBank: Nesvacumab (DB15330)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 1
Study: NCT01688960
Drug: nesvacumab (REGN910/ SAR307746)
Normalized name: Nesvacumab
DrugBank: Nesvacumab (DB15330)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 2
Study: NCT01688960
Drug: nesvacumab (REGN910/ SAR307746)
Normalized name: Nesvacumab
DrugBank: Nesvacumab (DB15330)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 3
Study: NCT01688960
Drug: aflibercept (ziv-aflibercept)
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose level 1
Study: NCT01688960
Drug: aflibercept (ziv-aflibercept)
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose level 2
Study: NCT00166881
Drug: Docetaxel-Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Docetaxel-Irinotecan, weekly, days 1, 8, 15, repeated every 4 weeks
Study: NCT02900235
Drug: MT-3995
Normalized name: lipase
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04642547
Drug: Lenvatinib and Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First week: Gefitinib: 125mg/day, oral; Lenvatinib: 8mg/day (weight ≤ 60Kg) or 12mg/day (weight \> 60Kg), oral.~One week later: Gefitinib: 250mg/day, oral; Lenvatinib: 8mg/day (weight ≤ 60Kg) or 12mg/day (weight \> 60Kg), oral.
Study: NCT02635386
Drug: Exenatide once weekly (EQW )
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 mg SC injection every 7 days
Study: NCT02635386
Drug: Dapagliflozin (DAPA)
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: One pill (10 mg) by mouth daily (QD) in am
Study: NCT02635386
Drug: Dapagliflozin plus Glucophage (MET ER)
Normalized name: metformin Extended Release Oral Tablet [Glucophage]
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: DAPA/MET ER-5 mg /1000 mg - 1 pill by mouth in am with food for 4 weeks DAPA/MET ER-10 mg /2000 mg - 2 pills in am by mouth with food -final dose
Study: NCT02635386
Drug: Phentermine /Topiramate (PHEN/ TPM) ER
DrugBank: Phentermine (DB00191)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PHEN 3.75/TPM ER 23mg - 1 pill by mouth once daily in am for 2 weeks. After 2 weeks, PHEN 7.5mg/TPM ER 46mg- 1 pill by mouth once daily in am
Study: NCT01216293
Drug: Dexlansoprazole
Normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexlansoprazole 60 mg capsules
Study: NCT01216293
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazole 40 mg capsules
Study: NCT01222221
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01080651
Drug: Voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Day1: voriconazole 200 mg x 2, oral administration, Day2-7: rifampin 600 mg, once a day oral administration, Day8: voriconazole 200 mg x 2 + rifampin 600 mg, oral co-administration
Study: NCT00216762
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituxan ® 1000 mg IV x 2 infusions, 2 weeks apart
Study: NCT04171349
Drug: Articaine
Normalized name: Articaine
DrugBank: Articaine (DB09009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vial
Study: NCT04171349
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vial
Study: NCT01062269
Drug: Cholestyramine
Normalized name: Cholestyramine
DrugBank: Cholestyramine (DB01432)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cholestyramine 4 grams one time dose
Study: NCT01062269
Drug: Cholestyramine
Normalized name: Cholestyramine
DrugBank: Cholestyramine (DB01432)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cholestyramine 12 grams one dose, one day
Study: NCT01062269
Drug: Tang
Normalized name: Stangard
DrugBank: Tangerine (DB10637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tang one dose one day
Study: NCT02990468
Drug: BMX-001
Normalized name: BMX-001 free base
DrugBank: BMX-001 free base (DB17516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection.
Study: NCT02990468
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin will be administered per institution's standard of care practice.
Study: NCT00745498
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml)
Study: NCT00430742
Drug: Taranabant
Normalized name: Taranabant
DrugBank: Taranabant (DB06624)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taranabant 0.5 mg, 1 mg capsule, 2 mg capsule once daily Treatment for 52 weeks.
Study: NCT01338558
Drug: bevacizumab [Avastin]
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5 mg/kg iv on Day 1 of each 2-week cycle until disease progression, unacceptable toxicity or withdrawal of consent
Study: NCT01338558
Drug: cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 400 mg /m2 iv on Day 1, followed by 250 mg/m2 every week until disease progression, unacceptable toxicity or withdrawal of consent
Study: NCT00298675
Drug: irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan administered weekly, IV.
Study: NCT00299806
Drug: Aliskiren
Normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
Approvals — FDA: yes, EMA: no, PMDA: no